Max Wallace, CEO of Accelerate Brain Cancer Cure, is a sought-after speaker at biotechnology conferences focusing on new approaches to funding treatments of the world’s most challenging diseases.
In March, Wake Forest Innovations invited Max to host a seminar titled, “From Biotech Entrepreneur to Venture Philanthropy.” Max discussed how venture philanthropies, like ABC2, are changing the landscape of biomedical research and accelerating the development of treatments and cures for a wide range of diseases. Members of the audience included representatives from small biotech startups and large pharmaceutical companies, as well as academic researchers.
Wake Forest Innovations is the new commercialization enterprise of Wake Forest Baptist Medical Center. It promotes new businesses and partnerships based on innovative products and services arising from the ideas, discoveries and the scientific research assets of Wake Forest Baptist Medical Center, a fully integrated, internationally recognized academic medical center in Winston-Salem, NC.
In April, Max was invited to speak at the inaugural Southeast Venture Philanthropy Summit in Chapel Hill, NC. Max discussed ABC2’s funding of targeted, individualized treatments for brain tumor patients on the panel, “Personalized Medicine - The New Paradigm for Developing Drugs for Smaller Populations.” Other contributors included Susan Braun, CEO, The V Foundation; James McCullough, CEO, Exosome Diagnostics; Lori Sames, Executive Director, Hannah’s Hope Fund and Geoff Ginsburg, MD, PhD, Duke Health System’s Center for Personalized Medicine.
The Summit brought some 200 leaders of regional life science companies and national disease foundations to Chapel Hill to explore alliances and new opportunities. It connected company leaders, academic researchers, funding specialists and executives from 30 foundations, including Accelerate Brain Cancer Cure, the Bill and Melinda Gates foundations and other major philanthropic groups targeting a wide range of diseases and conditions.
